Our results reveal new avenues for determining whether Nfil3 can enhance the BA-dependent microbiome in progressive MASLD and lead to the development of novel biomarkers and therapeutics. The gene discussed is NFIL3; the disease is metabolic dysfunction-associated steatotic liver disease.